Urologists’ Perceptions and Practice Patterns in Peyronie’s Disease: A Korean Nationwide Survey Including Patient Satisfaction

다국어 초록 (Multilingual Abstract)

Purpose: A nationwide survey was conducted of Korean urologists to illustrate physicians’perceptions and real practical patterns regarding Peyronie disease (PD).
Materials and Methods: A specially designed questionnaire exploring practice characteristicsand attitudes regarding PD, as well as patient satisfaction with each treatmentmodality, was e-mailed to 2,421 randomly selected urologists.
Results: Responses were received from 385 practicing urologists (15.9%) with a mediantime after certification as an urologist of 12 years. Regarding the natural course, 87%of respondents believed that PD is a progressive disease, and 82% replied that spontaneoushealing in PD occurred in fewer than 20% of patients. Regarding diagnosis ofPD, the methods used were, in order, history taking with physical examination (98%),International Index of Erectile Function questionnaires (40%), intracavernous injectionand stimulation (35%), and duplex sonography (28%). Vitamin E was most preferredas an initial medical management (80.2%), followed by phosphodiesterase-5 inhibitors(27.4%) and Potaba (aminobenzoate potassium, 20.1%). For urologists who administeredintralesional injection, the injected agent was, in order, corticosteroid(72.2%), verapamil (45.1%), and interferon (3.2%). The most frequently performed surgicalprocedure was plication (84.1%), followed by excision and graft (42.9%) and penileprosthesis implantation (14.2%). Among the most popular treatments in each modality,the urologists’ perceptions regarding the suitability of treatment and patient satisfactionwere significantly different, favoring plication surgery.
Conclusions: The practice pattern of urologists depicted in this survey is in line withcurrently available Western guidelines, which indicates the need for development offurther local guidelines based on solid clinical data.

참고문헌 (Reference)

1 Gontero P, "Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study" 6 : 558-566, 2009

2 Safarinejad MR, "Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study" 16 : 238-243, 2004

3 Schwarzer U, "The prevalence of Peyronie's disease: results of a large survey" 88 : 727-730, 2001

4 Gelbard MK, "The natural history of Peyronie's disease" 144 : 1376-1379, 1990

5 Teloken C, "Tamoxifen versus placebo in the treatment of Peyronie's disease" 162 : 2003-2005, 1999

6 Nicolosi A, "Sexual behaviour and dysfunction and help-seeking patterns in adults aged 40-80 years in the urban population of Asian countries" 95 : 609-614, 2005

7 Devine CJ Jr, "Proposal:trauma as the cause of the Peyronie's lesion" 157 : 285-290, 1997

8 Weidner W, "Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study" 47 : 530-535, 2005

9 Kadioglu A, "Peyronie’s disease: a guide to clinical management" Humana Press 9-18, 2007

10 류지간, "Peyronie’s Disease: Current Medical Treatment and Future Perspectives" 대한비뇨기과학회 50 (50): 527-533, 2009

11 Muller A, "Peyronie's disease intervention trials:methodological challenges and issues" 6 : 848-861, 2009

12 Taylor FL, "Peyronie's disease" 34 : 517-534, 2007

13 Jarow JP, "Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction" 158 : 1388-1390, 1997

14 Levine LA, "Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study" 5 : 1468-1473, 2008

15 Benson JS, "Penile shortening after radical prostatectomy and Peyronie's surgery" 10 : 468-474, 2009

16 Chung E, "Five-year follow-up of Peyronie's graft surgery: outcomes and patient satisfaction" 8 : 594-600, 2011

17 Kadioglu A, "Factors affecting the degree of penile deformity in Peyronie disease: an analysis of 1001 patients" 32 : 502-508, 2011

18 Shirazi M, "Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study" 41 : 467-471, 2009

19 Hatzimouratidis K, "EAU guidelines on penile curvature" 62 : 543-552, 2012

20 Pryor JP, "Controlled clinical trial of vitamin E in Peyronie’s disease" 9 : 41-45, 1983

21 El-Sakka AI, "Conservative treatment for Peyronie's disease: an update" 9 : 53-63, 2008

22 Safarinejad MR, "Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study" 178 (178): 1398-1403, 2007

23 Lemourt Oliva M, "Clinical evaluation of the use of propoleum in Peyronie's disease" 51 : 171-176, 1998

24 Mulhall JP, "An analysis of the natural history of Peyronie's disease" 175 : 2115-2118, 2006

25 Biagiotti G, "Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report" 88 : 63-67, 2001

26 Dibenedetti DB, "A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States" 2011 : 282503-, 2011

27 LaRochelle JC, "A Survey of primary-care physicians and urologists regarding Peyronie's disease" 4 (4): 1167-1173, 2007